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Summary
Antineoplastic drugs such as cisplatin, oxaliplatin, paclitaxel and vincristin are widely used in the treatment of several solid and blood tumours. However, the severity of peripheral neuropathy caused by these agents can affect the patient's quality of life.
The major symptoms of chemotherapy-induced peripheral neuropathy (CIPN) involve: sensory loss, paresthesia, dysesthaesia, numbness, tingling, temperature sensitivity, allodynia and hyperalgesia, in a "stocking and glove" distribution. Why many different chemotherapeutic agents result in similar neuropathy profiles is unclear. Many drug classes such as antidepressants, anticonvulsants, antispastic agents and others have been used in clinical practice, but there is no scientific evidence to prove their effectiveness. But drugs as the antioxidant have shown a protective effect against free radical damage. In order to find out a successful treatment for CIPN, animal studies (ie pharmacological and mechanical tests and histopathological immunohistochemical analyses) have been developed to try to determinate the action of the antioxidant agents. This review provides an overview of the major antioxidant agents recently investigated to treat CIPN and the animal models used for this purpose.
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| INTRODUCTION
Chemotherapy-induced peripheral neuropathy (CIPN) is the most common side effect caused by the antineoplastic treatment. Some drugs such as cisplatin, oxaliplatin, paclitaxel and vincristin are widely used in the treatment of several solid and blood tumours. However, the severity of peripheral neuropathy caused by these agents can affect the patient's quality of life and may result in chemotherapy dose reductions and even early discontinuation. 1, 2 Nearly, 48% of patients treated with multiple agents have some degree of CIPN, and the gravity of the effects depends on individual factors, cumulative dose, duration of exposure, drug chemical structure of antineoplastic agent and combination therapies. CIPN major symptoms involve: sensory loss, paresthesia, dysesthaesia, numbness, tingling, temperature sensitivity, allodynia and hyperalgesia, in a "stocking and glove" distribution.
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The explanation for many different chemotherapeutic agents resulting in similar neuropathy profiles it is still unclear. However, the effects of proinflammatory cytokines, such as interleukin (IL)-1β, IL-6, and tumour necrosis factor (TNF)-α, on neuronal tissues such as peripheral sensory neurons are regarded as a potential cause of CIPN.
Some studies also suggest anatomical and/or functional changes of nerve fibres and involvement of glial cells. Damage of some intracellular organelles such as mitochondria may also contribute to the neurotoxicity caused by chemotherapy. This review provides an overview of the major antioxidant agents recently investigated to treat CIPN, as well as the animal models used for this purpose. The search identified 815 files. In total 786 files were excluded for duplicity or lack of relevance after title and abstract analysis. We assessed the eligibility of the 26 resulting files after full reading. Finally, 25 articles were included in the study.
| CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY -MECHANISMS OF FORMATION

| Cisplatin
cisplatin-based chemotherapy is used for the treatment of several solid tumours, such as colorectal, ovarian, testicular, bladder, oesophagus, stomach and lung cancer. It is a representative drug in the platinum class, which has been used for four decades. The neurotoxicity induced by this drug is characterized by a dose-dependent painful or non-painful sensory neuropathy, mechanical and cold allodynia and ataxia. The range of neuropathy is between 24% and 92% of the patients and 20% of them are forced to stop treatment. Nevertheless, the mechanisms of cisplatin-induced (CISPLA) peripheral neuropathy are still unclear. OXALI has a better safety profile than do cisplatin and Carboplatin for auditory, haematologic and renal systems. However, it causes severe acute and chronic peripheral neuropathies, found in 85%-95% of all patients exposed to OXALI. Acute neuropathy occurs within hours of injection and is characterized by acral paresthesias enhanced by exposure to cold; it also sensitizes C-fibre afferents producing long-lasting Oxidative stress has also been suggested to be the direct cause The symptoms include mild tingling, spontaneous painful burning paresthesia and hyperalgesia. The mechanism through which VINCRI produces CIPN are still unclear, but it is known that VINCRI-induced neuropathic pain is due to neuronal toxicity and/or neurological disorder. 6, 8, 12 Abad et al. showed that VINCRI promotes inflammatory reactions in peripheral tissues and changes in spinal cord affecting A-fibres. Pain behaviour due to VINCRI may also be associated with dysfunction and increase in the discharge of C-fibres, but there is not much evidence. Heat hyperalgesia and mechanical allodynia were evaluated by Gao et al. 26 Spinal cords and dorsal root ganglia tissues were harvested for
The molecular actions of antineoplastic agents that cause peripheral nerve damage. Mitochondrial dysfunction occurs due to the opening of the transition pore of mitochondrial permeability, formation of oedema and vacuolization, which causes activation of caspases, thus leading the neuronal cell to apoptosis. Cisplatin and oxaliplatin also can affect both mitochondrial and neuronal DNA, leading to apoptosis. These changes stimulate microglial cells, which release proinflammatory mediators and growth factors into the damaged areas. Other proinflammatory mediators are also capable of damaging the myelin sheath. Oxaliplatin also alters Na + channel conductance through Ca 2+ chelation. These antineoplastic agents are also reported to cause peripheral sensitization through up regulation of N-methyl D-aspartate (NMDA) receptors, potentially translucidic vanilloid channels (TRPV) and protein kinase C (PKc)
analysing PKCε and TRPV1 expression levels. The plasma histamine levels also were assessed. The isoflavone Rotenone (mitochondrial complex I inhibitor) and Antimycin A (mitochondrial complex III inhibitor) were tested by Grffiths and Flatters, through Von Frey and rota-rod tests, for pharmacological modulation of mitochondrial ROS-producing sites and thus to produce antinociceptive effects on paclitaxel-induced neuropathy.
However, only the complex III activity inhibition showed positive results. 13 Ferulic Acid (a phenolic phytochemical commonly found in fruits and vegetables) and Matrine (an alkaloid found in plants from the Sophora genus) were able to reduce the signs of vincristin-induced peripheral neuropathy. The results were found through behavioural, electrophysiological, biochemical and histopathological analyses. 14 α-Lipoic acid as also been studied by Kahng and co-workers for treatment of vincristin-induced peripheral neuropathy. It was able to reduce mechanical and cold allodynia using Von Frey and Acetone tests.
29
Carvedilol is an antihypertensive drug that also presents antioxidant and mitoprotective properties. Areti and co-workers have shown T A B L E 1 (Continued) (Continues) that co-treatment with Carvedilol exhibited free radical scavenging activity against oxaliplatin-induced oxidative stress in neuronal cells, reducing the levels of nitrotyrosine and improving the mitochondrial superoxide dismutase expression in both sciatic nerve and dorsal root ganglia tissues.
23 Table 1 summarizes all antioxidant agents that were used and tests that were applied in each study.
| CONCLUSION
In an attempt to obtain an effective treatment for CIPN, the use of animal models has been fundamental to provide the survey archetype reproducible. As many drugs can cause CIPN, studies must take into account the particularities of the symptoms caused by each of them. Furthermore, it is increasingly necessary to understand the formation mechanisms of peripheral neuropathy are to better define the treatment targets. With an increasing amount of substances being studied, especially antioxidant agents, and the development of accurate techniques and tests, it is expected that soon the CIPN will be a treatable medical condition, with defined protocols, and postponement or interruption of antineoplastic treatment will no longer be necessary.
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